Rifapentine demonstrates efficacy for pregnant women, including those with HIV

Date: 03/14/2020

“A woman is more likely to develop tuberculosis (TB) in the first 90 days after she has a baby than at any other time in her life, especially if she has HIV,” Jyoti S. Mathad, MD, MS, assistant professor of medicine, obstetrics and gynecology, at Weill Cornell Medical College, told Healio. “WHO currently recommends that all people with HIV, including pregnant women, take medications to prevent TB, but a recent trial raised concerns about the most common regimen used during pregnancy: 6 months of daily isoniazid. That's a problem, because the more cutting-edge treatments, such as 3 months of weekly isoniazid and rifapentine (3HP), which has improved safety and adherence in nonpregnant people, has not been tested at all in pregnant women.”

(Access Full Article)

Clinical Trials

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More